OBJECTIVE: To evaluate, among anemic patients with HIV, the impact on hemoglobin (Hb) of initiating zidovudine (AZT)-containing and non-AZT-containing combination antiretroviral therapy (cART). METHODS: We used medical records data collected in 11 US cities from 1998 to 2004. Baseline anemia was described as mild (10 < Hb < or = 12 [women] or 14 [men] g/dL), moderate (8 < Hb < or = 10 g/dL), or severe (Hb < or = 8 g/dL). Improvement of anemia was a > or =1-g/dL increase in Hb, with a decrease in categoric severity. We excluded patients previously treated with erythropoietin or transfusion, and used Cox proportional hazards regression to describe factors associated with hazard of improvement of anemia. RESULTS: For 1620 patients initiating cART, more than half (54%) of patients had improvement of anemia. Time to improvement of anemia was longer for those initiating AZT-containing regimens and blacks and was shorter for those with moderate and severe anemia or CD4 counts <200 cells/microL. CONCLUSIONS: Most anemic patients initiating cART (with or without AZT) had increases in Hb-especially those with more severe anemia or immunosuppression. Initiation of AZT-containing cART may be considered, even for patients with preexisting anemia; however, improvement of anemia may be delayed for black patients and for patients with mild disease.
OBJECTIVE: To evaluate, among anemicpatients with HIV, the impact on hemoglobin (Hb) of initiating zidovudine (AZT)-containing and non-AZT-containing combination antiretroviral therapy (cART). METHODS: We used medical records data collected in 11 US cities from 1998 to 2004. Baseline anemia was described as mild (10 < Hb < or = 12 [women] or 14 [men] g/dL), moderate (8 < Hb < or = 10 g/dL), or severe (Hb < or = 8 g/dL). Improvement of anemia was a > or =1-g/dL increase in Hb, with a decrease in categoric severity. We excluded patients previously treated with erythropoietin or transfusion, and used Cox proportional hazards regression to describe factors associated with hazard of improvement of anemia. RESULTS: For 1620 patients initiating cART, more than half (54%) of patients had improvement of anemia. Time to improvement of anemia was longer for those initiating AZT-containing regimens and blacks and was shorter for those with moderate and severe anemia or CD4 counts <200 cells/microL. CONCLUSIONS: Most anemicpatients initiating cART (with or without AZT) had increases in Hb-especially those with more severe anemia or immunosuppression. Initiation of AZT-containing cART may be considered, even for patients with preexisting anemia; however, improvement of anemia may be delayed for black patients and for patients with mild disease.
Authors: Amy C Justice; Kathleen A McGinnis; Janet P Tate; R Scott Braithwaite; Kendall J Bryant; Robert L Cook; E Jennifer Edelman; Lynn E Fiellin; Matthew S Freiberg; Adam J Gordon; Kevin L Kraemer; Brandon D L Marshall; Emily C Williams; David A Fiellin Journal: Drug Alcohol Depend Date: 2016-01-29 Impact factor: 4.492
Authors: Deidra D Parrish; Meridith Blevins; Karen M Megazzini; Bryan E Shepherd; Mukhtar Y Mohammed; C William Wester; Sten H Vermund; Muktar H Aliyu Journal: Int J STD AIDS Date: 2013-10-08 Impact factor: 1.359
Authors: Julia Z Xu; Richard O Francis; Leonel E Lerebours Nadal; Maryam Shirazi; Vaidehi Jobanputra; Eldad A Hod; Jeffrey S Jhang; Brie A Stotler; Steven L Spitalnik; Stephen W Nicholas Journal: Am J Trop Med Hyg Date: 2015-08-03 Impact factor: 2.345
Authors: Devan Jaganath; A Sarah Walker; Francis Ssali; Victor Musiime; Francis Kiweewa; Cissy Kityo; Robert Salata; Peter Mugyenyi Journal: AIDS Res Hum Retroviruses Date: 2014-02-07 Impact factor: 2.205
Authors: Andrew D Kerkhoff; Robin Wood; Frank G Cobelens; Ankur Gupta-Wright; Linda-Gail Bekker; Stephen D Lawn Journal: BMC Med Date: 2015-04-02 Impact factor: 8.775
Authors: Andrew D Kerkhoff; Robin Wood; Frank G Cobelens; Ankur Gupta-Wright; Linda-Gail Bekker; Stephen D Lawn Journal: BMC Infect Dis Date: 2014-12-21 Impact factor: 3.090